Get regular updates to your inbox.
By analyzing available research and conducting nearly 100 interviews with patients, an international team of researchers crafted a new tool to measure the severity of myasthenia gravis (MG) based on patient experiences. Called MG Symptoms PRO, this tool has the potential to aid clinical trials by better capturing a…
Read more
Argenx is working toward the commercial launch of Vyvgart (efgartigimod) — recently approved by the U.S. Food and Drug Administration (FDA) — to treat adults in the U.S. with generalized myasthenia gravis (gMG) who have the most common type of MG-driving antibody. Vyvgart currently is up for…
Immunovant is moving forward with its Phase 3 clinical trial in the U.S. to evaluate the investigational myasthenia gravis (MG) therapy batoclimab in the first half of this year. The announcement came after the company reached an agreement with the division of neurology within the U.S. Food…
In her columns debut, Shawna Barnes shares her journey toward diagnosis and explains the story behind “The Whispered Roar.”
Visit the Myasthenia Gravis News forums to connect with others in the myasthenia gravis community.
Becoming educated and informed about MG is a good first step. Learn general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your MG journey.
There is no cure for MG yet, but there are treatments that can help manage the disease. Learn more about approved and experimental therapeutic approaches here.
Get regular updates to your inbox.
